| 752 | 0 | 613 |
| 下载次数 | 被引频次 | 阅读次数 |
随着糖尿病成为一项全球性的健康问题，传统的管理方法在个体化治疗和持续监测方面面临挑战。研究在梳理目前人工体外胰腺设备所用的自动胰岛素输注系统的基础上，提出结合人工智能(artificial intelligence, AI)舌诊及体质辨识系统、个性化中医药干预系统构建基于“互联网+中医药”的人工体外胰腺设备，着力于通过结合先进的技术和中医药理论，实现精准的血糖控制，并为糖尿病患者提供个性化中医药干预建议。该设备将目前已有的混合闭环胰岛素输注系统为基础，按照图像数据获取、图像预处理、图像分割、中医诊疗算法集成、预判模型训练等流程，构建AI舌诊及体质辨识系统和个性化中医药干预系统，实现设备下的三系统联动，期望为构建具有中医药特色的人工体外胰腺设备提供思路，进一步促进中医药智能化的应用与发展。
Abstract：As diabetes mellitus has become a global health problem, traditional management methods face challenges in individualised treatment and continuous monitoring. In this study, on the basis of the automatic insulin infusion system used in the current artificial extracorporeal pancreas device, it proposes to construct an artificial extracorporeal pancreas device based on “Internet+traditional Chinese medicine” by combining the AI tongue diagnosis and constitution recognition system and personalised traditional Chinese medicine(TCM) intervention system, and it focuses on the combination of advanced technology and TCM theory to achieve accurate glucose control and provide personalised TCM intervention suggestions for diabetic patients. Based on the existing hybrid closed-loop insulin infusion system, the device will construct an AI tongue diagnosis and constitution recognition system and a personalised TCM intervention system in accordance with the processes of image data acquisition, image pre-processing, image segmentation, TCM diagnosis and treatment algorithm integration, and prognostic model training, so as to realize the linkage of the three systems under the device. This study is expected to provide ideas for the construction of artificial extracorporeal pancreatic devices with traditional Chinese medicine characteristics, and further promote the application and development of intelligent Chinese medicine.
[1] PHILLIP M,NIMRI R,BERGENSTAL R M,et al.Consensus recommendations for the use of automated insulin delivery technologies in clinical practice[J].Endocr Rev,2023,44(2):254-280.
[2] BUCKINGHAM B,BECK R W,RUEDY K J,et al.Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes[J].Diabetes Care,2013,36(12):4030-4035.
[3] LI N,ZHANG H L,LI X H.Advances in research on the protective mechanisms of traditional Chinese medicine (TCM) in islet β cells[J].Evid Based Complementary Altern Med,2019,2019:7526098.
[4] LI Z,SHANGGUAN Z,LIU Y,et al.Puerarin protects pancreatic β-cell survival via PI3K/Akt signaling pathway[J].J Mol Endocrinol,2014,53(1):71-79.
[5] SANCHES J R,FRAN?A L M,CHAGAS V T,et al.Polyphenol-rich extract of Syzygium cumini leaf dually improves peripheral insulin sensitivity and pancreatic islet function in monosodium L-glutamate-induced obese rats[J].Front Pharmacol,2016,7:48.
[6] American Diabetes Asscociation.Standards of Care in Diabetes-2024[J].Diabetes Care,2024,47(Suppl 1):13-21.
[7] COBRY E C,BERGET C,MESSER L H,et al.Review of the omnipod? 5 automated glucose control system powered by horizonTM for the treatment of type 1 diabetes[J].Ther Deliv,2020,11(8):507-519.
[8] SAUNDERS A,MESSER L H,FORLENZA G P.MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus:overview of its safety and efficacy[J].Expert Rev Med Devices,2019,16(10):845-853.
[9] SHERWOOD J S,RUSSELL S J,PUTMAN M S.New and emerging technologies in type 1 diabetes[J].Endocrinol Metab Clin North Am,2020,49(4):667-678.
[10] KESAVADEV J,SABOO B,KRISHNA M B,et al.Evolution of insulin delivery devices:from syringes,pens,and pumps to DIY artificial pancreas[J].Diabetes Ther,2020,11(6):1251-1269.
[11] PEACOCK S,FRIZELLE I,HUSSAIN S.A systematic review of commercial hybrid closed-loop automated insulin delivery systems[J].Diabetes Ther,2023,14(5):839-855.
[12] FORLENZA G P,BUCKINGHAM B A,BROWN S A,et al.First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes[J].Diabetes Technology & Therapeutics,2020,23(6):546.
[13] BROWN S A,KOVATCHEV B P,RAGHINARU D,et al.Six-month randomized,multicenter trial of closed-loop control in type 1 diabetes[J].N Engl J Med,2019,381(18):1707-1717.
[14] BROWN S A,FORLENZA G P,BODE B W,et al.Multicenter trial of a tubeless,on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes[J].Diabetes Care,2021,44(7):1630-1640.
[15] DAVIS G M,PETERS A L,BODE B W,et al.Safety and efficacy of the omnipod 5 automated insulin delivery system in adults with type 2 diabetes:from injections to hybrid closed-loop therapy[J].Diabetes Care,2023,46(4):742-750.
[16] 段梦遥，毛伯，周恒宇，等.不同中医体质类型的舌象特征定量分析[J].中华中医药杂志，2023,38(10):4955-4958.
[17] 田桐，孙丽平.长春中医药大学附属医院609名体检儿童中医体质与舌象关系调查分析[J].中国医药导报，2022,19(5):64-67.
[18] 黄冕，张梦圆，陈佳，等.体胖儿童102例体质类型与面象、舌象特征相关性研究[J].中华中医药杂志，2020,35(2):888-891.
[19] 屈德春，吕琨，朱跃坤，等.结直肠癌患者舌苔变化与舌苔菌群和肠道菌群的相关性研究[J].世界中医药，2024,19(12):1802-1810.
[20] 郝一鸣，王忆勤，张之辰，等.2型糖尿病患者舌象参数特征及与空腹血糖的相关性初探[J].时珍国医国药，2017,28(1):253-255.
[21] 贺宏波，闫韶哗，杨玲玲，等.5930例2型糖尿病患者舌象与实验室指标相关性分析[J].中医杂志，2013,54(23):2031-2034.
[22] 陈清光，蔡梦洁，袁培琼，等.不同糖代谢人群的舌象客观化特征研究[J].辽宁中医杂志，2021,48(3):88-91.
[23] 杨睿博，张艳，罗文轩，等.不同病程2型糖尿病患者舌象的相关因素研究[J].环球中医药，2023,16(11):2232-2239.
[24] LIAN F M,WU L,TIAN J X,et al.The effectiveness and safety of a Danshen-containing Chinese herbal medicine for diabetic retinopathy:a randomized,double-blind,placebo-controlled multicenter clinical trial[J].J Ethnopharmacol,2015,164:71-77.
[25] XU J,LIAN F,ZHAO L,et al.Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula[J].ISME J,2015,9(3):552-562.
[26] LIU X Y,LIU L,CHEN P Y,et al.Clinical trials of traditional Chinese medicine in the treatment of diabetic nephropathy—a systematic review based on a subgroup analysis[J].J Ethnopharmacol,2014,151(2):810-819.
[27] SUN J,REN J G,HU X J,et al.Therapeutic effects of Chinese herbal medicines and their extracts on diabetes[J].Biomed Pharmacother,2021,142:111977.
基本信息:
DOI：10.13193/j.issn.1673-7717.2025.10.003
中图分类号:TP393.09;R2-03
引用信息:
[1]幸享玲,王烨曼,陈璐瑶,等.基于“互联网+中医药”的人工体外胰腺设备构建研究[J].中华中医药学刊,2025,43(10):15-18+259.DOI:10.13193/j.issn.1673-7717.2025.10.003.
基金信息:
中华人民共和国文化和旅游部国家级非物质文化遗产代表性项目(205IX-2); 江苏省卫生健康委员会国医大师周仲瑛甲状腺疾病辨治规律挖掘及临床决策支持系统构建与应用项目(Z2020024); 江苏省六大人才高峰项目(RJFW-40); 江苏省“333高层次人才培养工程”项目(2018III-0121); 江苏省科技型企业技术创新资金项目(BC2015022); 南京市非物质文化遗产代表性项目(NJVIII-20); 南京市浦口区非物质文化遗产代表性项目(PKIX-4)